SEC Form 4 · accession 0001209191-17-039792
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Aselage
Officer — Chief Executive Officer · Director
Period of report
Jun 14, 2017
Accepted (ET)
Jun 14, 2017 · 2:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 14, 2017 | P | 5,000 | $17.85 | D | 245,556 | D |
Table II — derivative securities
No Table II lines on this filing.